239 related articles for article (PubMed ID: 32214375)
1. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.
Dubrall D; Schmid M; Stingl JC; Sachs B
PLoS One; 2020; 15(3):e0230632. PubMed ID: 32214375
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
3. Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
Schlienger RG; Korn JR; Wehler E; Lopez Leon S; Yeaw J
Am J Cardiovasc Drugs; 2017 Dec; 17(6):465-474. PubMed ID: 28779444
[TBL] [Abstract][Full Text] [Related]
4. Incidence of angio-oedema associated with ARBs, ACE inhibitors, and aliskiren.
BMJ; 2012 Oct; 345():e6941. PubMed ID: 23077371
[No Abstract] [Full Text] [Related]
5. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
6. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
[TBL] [Abstract][Full Text] [Related]
7. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
8. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.
Alharbi FF; Kholod AAV; Souverein PC; Meyboom RH; de Groot MCH; de Boer A; Klungel OH
Fundam Clin Pharmacol; 2017 Dec; 31(6):676-684. PubMed ID: 28767167
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
[TBL] [Abstract][Full Text] [Related]
10. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.
Siragy HM
Vasc Health Risk Manag; 2011; 7():297-313. PubMed ID: 21633727
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
[TBL] [Abstract][Full Text] [Related]
13. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink.
Mahmoudpour SH; Baranova EV; Souverein PC; Asselbergs FW; de Boer A; Maitland-van der Zee AH;
Br J Clin Pharmacol; 2016 Dec; 82(6):1647-1659. PubMed ID: 27524468
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
[TBL] [Abstract][Full Text] [Related]
15. Angioedema related to Angiotensin inhibitors.
Knecht SE; Dunn SP; Macaulay TE
J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
[TBL] [Abstract][Full Text] [Related]
16. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren in the treatment of hypertension and organ damage.
Riccioni G
Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
[TBL] [Abstract][Full Text] [Related]
18. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.
White WB; Bresalier R; Kaplan AP; Palmer BF; Riddell RH; Lesogor A; Chang W; Keefe DL
J Clin Hypertens (Greenwich); 2010 Oct; 12(10):765-75. PubMed ID: 21029339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
